Eric Pfanner

2 weeks ago | news.bloomberglaw.com | Eric Pfanner |Rachel Phua

Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.

2 weeks ago | news.bloombergtax.com | Eric Pfanner |Rachel Phua

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.

2 weeks ago | modernhealthcare.com | Eric Pfanner |Rachel Phua

Breadcrumb Home Digital Health May 21, 2025 09:36 AM Tweet Share Share Email More Reprints Print Getty Images Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the U.S.-China trade dispute threatens its earnings.

2 weeks ago | bloomberg.com | Eric Pfanner |Rachel Phua

(Bloomberg) -- Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.

3 weeks ago | bloomberglinea.com.br | Eric Pfanner

Bloomberg — A Novo Nordisk destituiu o CEO Lars Fruergaard Jorgensen enquanto a farmacêutica luta contra a crescente concorrência para seu tratamento de obesidade Wegovy, que tem pesado sobre o preço das ações. A empresa dinamarquesa disse que Jorgensen está saindo por acordo mútuo com o conselho, embora ele continue como chefe “por um período para apoiar uma transição suave para uma nova liderança”. A busca por um novo líder já começou, disse a empresa em um comunicado na sexta-feira (16).